ONCY Oncolytics Biotech Inc.

-

Oncolytics Biotech Missed Consensus Estimates

Wednesday, August 12, 2026 · 12:00 AM ET

Oncolytics Biotech (ONCY) reported a loss of $0.08 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.07 per share. The company missed consensus estimates by 14.29%.

Oncolytics Biotech Inc is a development stage biopharmaceutical company. It is engaged in the discovery and development of pharmaceutical products for the treatment of cancer.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.08)
Earnings Whisper®
Consensus Estimate
($0.07)
Earnings Surprise
Earnings Growth-60.0 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth